Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ARVN

Arvinas, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ARVN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.24

Arvinas, Inc. (NASDAQ: ARVN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:15 UTC.

What Arvinas, Inc. does

Ethos Technologies is a clinical-stage biotechnology company developing PROTAC protein degraders, a new class of therapeutics that use the body's natural protein disposal system to eliminate disease-causing proteins. The company has designed a proprietary PROTAC Discovery Engine to discover therapeutics targeting diseases caused by abnormal or excess proteins, including historically difficult-to-treat targets.

Summarized from Arvinas, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.24
Return on equity-18.62%

Revenue, margins & earnings

FY2021: net loss $191M on revenue $54M$54MFY2021FY2022: net loss $282M on revenue $131M$131MFY2022FY2023: net loss $367M on revenue $78M$78MFY2023FY2024: net loss $199M on revenue $263M$263MFY2024FY2025: net loss $81M on revenue $263M$263MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-26
Most recent filed transactions — June 2026:
  • 2026-06-26DirectorAward15,527—
  • 2026-06-26DirectorStock Option (right to buy)Award22,714—
  • 2026-06-26DirectorAward15,527—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Arvinas, Inc. do?

Ethos Technologies is a clinical-stage biotechnology company developing PROTAC protein degraders, a new class of therapeutics that use the body's natural protein disposal system to eliminate disease-causing proteins.

When did ARVN last file with the SEC?

Arvinas, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-25. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:15 UTC. This page is also available as JSON at /api/data?ticker=ARVN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ARVN and 5,000+ tickers.

Create a free account — keep ARVN
For your agent
GET /api/data?ticker=ARVN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt